Omaha
NPPES registry listings, primary taxonomy, retrieved 2026-10-27
148- Orthopaedic Surgery
- 148
Documentation a Nebraska practice should expect
Each lot of a Wharton's jelly or exosome product carries a unique identifier that traces back to donor screening, processing and third-party sterility testing records, and a verified account can request the certificate of analysis and lot release record for that specific lot. Nebraska medical directors and their counsel are responsible for determining how a product and its intended use fit their own regulatory review, and should direct specific questions to the Nebraska medical board rather than rely on a distributor's description.
- Certificate of analysis for the lot
- Donor eligibility and screening summary
- Sterility testing record from quarantine release
How orthopedic groups typically vet a new supplier
A multi-physician orthopedic group evaluating a biologics distributor generally assigns the review to practice administration rather than a single surgeon, and that review covers donor screening practices, whether sterility testing is completed on every lot before release, and whether the distributor can connect a physician to someone who can walk through the documentation. None of that review substitutes for the practice's own determination of regulatory fit.
Shipping into the Midwest
Cryopreserved Wharton's jelly formats ship overnight on dry ice in validated containers maintaining -80 degrees Celsius, timed so the shipment reaches an Omaha-area practice with the dry ice intact; a staff member should be scheduled to receive and log the delivery the day it is due. Lyophilized exosome and Wharton's jelly formats ship and store at room temperature per the product insert, which removes the need for cold-chain receiving.
Opening a verified account
Ordering is limited to accounts verified against a practice's NPI number, in line with the policy of selling only to licensed clinics and physicians. An Omaha-area orthopedic practice sets up an account the same way as any other practice nationally: submit the NPI and basic intake information, and a representative confirms the account before documentation and ordering access are released.
FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
Does Precision Biologics have local representatives in Omaha?+
No. Accounts are managed through a national NPI-verification process rather than a local sales presence.
How quickly can an orthopedic group get a certificate of analysis for a lot?+
Lot-specific documentation is issued to verified accounts in connection with an order; general program documentation is available before an account is set up.
Who determines whether a product fits a given orthopedic use?+
The treating physician and the practice's own regulatory counsel make that determination. Precision Biologics supplies documentation but does not advise on clinical use.